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OBJECTIVES We compared outcomes following thrombolytic therapy and primary angioplasty with no
reperfusion therapy in a population-based cohort of older patients presenting with acute
myocardial infarction (AMI) and indications for acute reperfusion.
BACKGROUND Evidence supporting the efficacy of acute reperfusion (thrombolytic therapy or primary
angioplasty) in the elderly with suspected AMI is not as strong as it is in younger groups.
METHODS From a national cohort of Medicare beneficiaries with AMI, we identified 37,983 patients age
65 or older who presented within 12 h of symptom onset with ST elevation or left bundle
branch block. A total of 14,341 (37.8%) received thrombolytic therapy and 1,599 (4.2%)
underwent primary angioplasty within 6 h of hospital arrival.
RESULTS After adjustment for demographic, clinical, hospital and physician factors, and co-
interventions, thrombolytic therapy was not associated with a better 30-day survival (odds
ratio [OR] 1.01; 95% confidence interval [CI]: 0.94 to 1.09) compared with no therapy,
whereas primary angioplasty was (OR 0.79; 95% CI: 0.66 to 0.94). At one year, both
thrombolytic therapy (OR 0.84; 95% CI: 0.79 to 0.89) and primary angioplasty (OR 0.71;
95% CI: 0.61 to 0.83) were associated with a survival benefit.
CONCLUSIONS In this national sample of older patients, those who received thrombolytic therapy or primary
angioplasty had lower mortality at one year compared with those who did not receive a
reperfusion strategy. However, only primary angioplasty was associated with better survival at
30 days. Our findings should heighten interest in further investigating the best approach to
the treatment of older patients with suspected AMI and ST segment elevation or left bundle
branch block. (J Am Coll Cardiol 2000;36:366–74) © 2000 by the American College of
Cardiology
Clinical practice guidelines issued by the American College
of Cardiology (ACC) and the American Heart Association
(AHA) strongly endorse the use of reperfusion therapy for
the treatment of patients without contraindications who
present within 12 h of the onset of chest pain and have
ST-segment elevation or left bundle branch block (LBBB)
(1). The recommendation for early thrombolytic therapy is
based on evidence from the more than 60,000 patients who
have been studied in placebo-controlled randomized trials
(2). The more recent recommendation of primary angio-
plasty as an alternative to thrombolytic therapy comes from
a series of randomized clinical trials comparing these two
reperfusion therapies (3). As a result, the use of reperfusion
therapy for appropriate patients is considered an indicator of
the quality of care (4).
The efficacy of thrombolytic therapy in elderly patients
has not been evaluated to the same extent as it has in
younger groups. Early thrombolytic trials enrolled relatively
few older patients and demonstrated a relatively small
benefit. Pooled data from the large clinical trials showed
that the 35-day mortality of patients 75 years of age and
older was 24.3% for those treated with thrombolytic therapy
and 25.3% for the placebo group (2). Although recent
analyses comparing primary angioplasty with thrombolytic
therapy among the elderly have suggested a survival benefit
with early coronary intervention, these studies have not
included comparison to a group that did not receive reper-
fusion therapy (3,5). Thus, even though evidence is accu-
mulating that angioplasty may offer an alternative to throm-
bolytic therapy, it remains unclear whether any reperfusion
therapy is more effective than no reperfusion therapy in
older patients. This issue is particularly important given that
the use of thrombolytic therapy in the elderly is increasing
(6), and prompt angioplasty is not an option in many
hospitals (6). In recognition of this limited evidence, the
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ACC/AHA guidelines initially suggested that the treatment
of older patients was not strongly indicated, and even now
do not endorse it with the same enthusiasm that they do for
younger patients (1).
We undertook this study to assess the effectiveness of
thrombolytic therapy in the elderly using the Cooperative
Cardiovascular Project (CCP), a Health Care Financing
Administration initiative to improve the quality of care for
Medicare beneficiaries with acute myocardial infarction
(AMI). Our primary aim was to determine if thrombolytic
therapy is associated with a better outcome than no reper-
fusion therapy. We also included comparisons with patients
who underwent primary angioplasty. As a secondary objec-
tive, we sought to identify whether there were specific
subgroups in which thrombolytic therapy provided a sur-
vival benefit.
METHODS
Study sample. The patient cohort in this study is derived
from the CCP national sample. The CCP database contains
detailed clinical data on 234,769 patients with a principal
discharge diagnosis of AMI (International Classification of
Diseases, Ninth Revision, Clinical Modification [ICD-9-
CM] 410) between January 1994 and February 1996 (7).
We restricted the study sample to patients who were 65
years of age or older who had clinical and electrocardio-
graphic features upon presentation, making them appropri-
ate for consideration for acute reperfusion: they presented
directly to the index hospital within 12 h of symptom onset
with ST-segment elevation of at least 1 mm in at least 2
contiguous leads or LBBB (1). We restricted the study
sample to the first AMI admission for any given individual
in the CCP cohort and excluded patients who were trans-
ferred into the hospital.
The primary cohort consisted of patients without any
absolute contraindications to thrombolytic therapy: active
bleeding on arrival, a history of bleeding disorder, stroke
within the past year (see following text) or terminal illness.
We derived an ideal subgroup of patients for reperfusion
therapy by further restricting the primary cohort to patients
presenting within 6 h of symptom onset and having no
absolute or relative contraindications to thrombolytic ther-
apy. Relative contraindications included prior internal
bleeding, recent trauma or surgery, recent cardiopulmonary
resuscitation, any prior stroke, blood pressure .180/110 on
arrival, patient or physician refusal of thrombolytic therapy,
current use of warfarin with an International Normalized
Ratio .2 or a prothrombin time (PT) .16 s. Patients with
cancer or dementia, those admitted from a nursing home
and those with a do-not-resuscitate order on arrival were
also excluded from the ideal group to eliminate patients at
high risk of mortality from competing comorbidity. Finally,
we excluded from the ideal cohort patients with cardiogenic
shock, a group in which the decision-making process is
somewhat more complex and controversial (8).
Data source. The data elements collected as part of the
CCP have been reported previously (7) and included more
than 140 variables for each patient. Trained medical record
reviewers abstracted patient demographics, past cardiac and
noncardiac history, admission characteristics, diagnostic test
results (including measurement of ST elevation for each
electrocardiographic lead) and information on in-hospital
events and procedures. The high reliability of the abstrac-
tion process has been reported (9). Documentation of
angioplasty required that a coronary intervention had been
attempted; cardiac catheterizations without associated cor-
onary interventions did not qualify. Stroke during the year
before discharge was identified by merging the CCP records
with Medicare Part A hospital claims, and searching the
UB-92 principal and secondary diagnosis codes (ICD-
9-CM codes 430, 431, 432.1, 432.9, 436).
Hospital characteristics, including annual volume of AMI
and the ability to perform on-site coronary angioplasty, were
obtained from the American Hospital Association database
(10). The attending physician was identified from Medicare
Part A hospitalization claims; specialty was determined
through linkage with the American Medical Association
Physician Masterfile. Dates of death in the Medicare
Enrollment Database were derived from the discharge dates
of billing records indicating a discharge disposition of death
and from the Master Beneficiary Record. The use of the
Medicare Enrollment Database to establish the time of
death has been validated (11).
Statistical analysis. The primary cohort, consisting of
patients without absolute contraindications to thrombolytic
therapy, was divided into three subgroups on the basis of
primary reperfusion strategy. The cohort receiving throm-
bolytic therapy included patients who received this agent
within 6 h of arrival at the hospital. The cohort undergoing
primary angioplasty included patients who received angio-
plasty as the first reperfusion strategy within 6 h of hospital
arrival. For the 1.5% of patients who underwent both
thrombolytic therapy and angioplasty, cohort assignment
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was based on the first treatment. The remaining patients,
including those who had not received reperfusion therapy
within 6 h of hospital arrival, constituted the reference
group. The 6-h limit for door-to-therapy time was designed
to select patients who were most likely treated as part of an
initial clinical strategy and not as a response to a change in
clinical status.
We evaluated the bivariate association between each
reperfusion strategy and the demographic, clinical, hospital,
physician and co-intervention variables. Categorical charac-
teristics were compared with the chi-square test and con-
tinuous values were compared using the Wilcoxon rank-sum
test. The results are reported as means 6 standard devia-
tion.
We developed a series of logistic models to determine the
association of thrombolytic therapy and primary angio-
plasty, compared with the no-reperfusion strategy, with
both 30-day and one-year mortality. The initial model
examined the unadjusted risks of early thrombolytic therapy
and primary angioplasty, with the no-reperfusion subgroup
serving as the reference. Demographic characteristics, in-
cluding age, race, and gender, were then included in the
next model. Adjustment for imbalances in other patient
characteristics was performed by adding covariates from the
previously published Global Utilization of Steptokinase and
Tissue Plasminogen Activator for Occluded Coronary Ar-
teries (GUSTO-1) mortality model (systolic blood pressure
at admission, pulse, location of AMI, Killip class, height,
weight, history of infarction, history of bypass surgery,
smoking status, and the presence or absence of diabetes,
hypertension and cerebrovascular disease) to the logistic
model (12). As a surrogate for myocardium at risk, we
identified the number of leads with ST elevation and
calculated the sum of ST elevation in all leads (except AVR)
of the initial electrocardiogram. We also included in our
candidate model variables additional clinical characteristics
associated with mortality in older, sicker cohorts: impaired
mobility, serum creatinine, urinary incontinence, dementia,
cancer, chronic obstructive pulmonary disease, do-not-
resuscitate status on arrival, and admission from a nursing
home. We then expanded the model to incorporate hospital
and physician characteristics including physician specialty,
annual hospital AMI volume and interventional facilities. In
the final model, we included the use of aspirin and beta-
blockers on arrival to adjust for co-interventions that may
have had a beneficial impact on mortality. In each step, all
the covariates were forced into the model.
We repeated the logistic models after stratifying the
cohort by age, gender, the extent of ST-segment elevation
and hospitalization at a facility with on-site angioplasty.
Then, using the criteria outlined above, we evaluated the
effect of the reperfusion strategies on a very restricted group
of patients without absolute or relative contraindications to
thrombolytic therapy and with minimal comorbidity (the
“ideal cohort”).
Next, we developed a multivariate logistic regression
model with thrombolytic therapy as the dependent variable
to estimate the propensity of receiving thrombolytic therapy
(13). The demographic, clinical, hospital and co-
intervention variables were added in a stepwise fashion with
an entry and exit significance level of 0.0001. The strict
entry criteria were used because of the large size of the study
sample and the number of variables examined. With this
model, patients were ranked by their likelihood of receiving
thrombolytic therapy. Patients in the lowest quintile con-
stituted the “lowest-likelihood” group, whereas those in the
highest quintile represented the “highest-likelihood” group.
We then evaluated the outcomes following thrombolytic
therapy, primary angioplasty, or neither within both the
“lowest-likelihood” and “highest-likelihood” groups.
Finally, we investigated the influence of the type of
thrombolytic agent and the delay in thrombolytic treatment
(door-to-therapy time). For type of agent, we report the
results for streptokinase and tissue plasminogen activator
(tPA), the two most commonly used thrombolytic agents.
For the delay analysis we used the ACC/AHA guidelines to
define “delay” as the administration of thrombolytic therapy
more than 30 min after arrival at the hospital (1).
For all models, calibration was evaluated by comparing
fitted probabilities of thrombolytic therapy with observed
use within quintiles of likelihood (14). Discrimination was
evaluated by calculating an area under the receiver operating
characteristic curve for each model (15). The statistical
analyses were performed with the SAS 6.12 software pack-
age (16).
RESULTS
Baseline Characteristics. From among the 234,769 pa-
tients in the CCP database, 40,563 (17.2%) were at least 65
years old, presented directly to the index hospital within
12 h of the onset of chest pain and had ST-segment
elevation or LBBB. After exclusion of patients for whom
the time of therapy was not recorded, 39,212 patients
remained for analysis. From this group, 1,229 patients were
excluded because of the presence of at least one absolute
contraindication to thrombolytic therapy, leaving a sample
size of 37,983 patients (Table 1).
Among the study sample, 14,341 (37.8%) patients re-
ceived thrombolytic therapy and 1,599 (4.2%) underwent
primary angioplasty; 22,043 (58.0%) patients did not un-
dergo reperfusion therapy. The mean times to thrombolytic
treatment and primary angioplasty after reaching the hos-
pital were 62 (6 48) min and 131 (6 60) min, respectively.
Table 2 reports the comparison of the treatment groups.
Patients not receiving reperfusion therapy were older, more
likely to be female, and more likely to have a history of
hypertension, diabetes, AMI, heart failure, prior coronary
artery bypass surgery and noncardiac comorbidity. Patients
not receiving thrombolytic therapy or primary angioplasty
were more likely to have LBBB and nonanterior location of
infarction, and less likely to have dramatic ST elevation.
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Patients receiving primary angioplasty and thrombolytic
therapy were more likely to have been cared for by a
cardiologist and were more likely to be treated with aspirin
and beta-blockers.
Patients who received thrombolytic therapy had an un-
adjusted 30-day mortality rate of 13.5% (p 5 0.001) and
patients who underwent primary angioplasty had a 30-day
mortality rate of 13.0% (p 5 0.001) compared with 20.6%
for patients who did not receive reperfusion therapy (Table
3). Among patients who died within 30 days, treatment
with thrombolytic therapy was associated with earlier mor-
tality (median of two days for patients receiving thrombo-
lytic therapy, three days for those undergoing primary
angioplasty and four days for those not receiving either
therapy). At one year, the unadjusted mortality rates were
similar between patients undergoing primary angioplasty
(19.3%, p 5 0.001) and thrombolytic therapy (19.5%, p 5
0.001), and significantly lower than for patients not receiv-
ing reperfusion (36.9%).
In contrast to patients not treated with reperfusion
therapy, the risk of developing post-infarction angina or
heart failure during index hospitalization was lower in
patients receiving thrombolytic therapy and primary angio-
plasty (Table 3). Patients receiving thrombolytic therapy
had a higher rate of intracranial hemorrhage (1.5%, p 5
0.001) and total stroke (3.1%, p 5 0.07) than those not
receiving reperfusion (0.1% and 2.7%, respectively). Patients
who had thrombolytic therapy were more likely to have a
subsequent cardiac catheterization, coronary angioplasty,
and coronary artery bypass than patients who did not
undergo early reperfusion therapy.
Multivariate analysis. The logistic models for mortality
were adjusted for demographic, clinical, hospital and phy-
sician characteristics, medical history, electrocardiographic
factors and co-interventions. These variables produced mor-
tality models with good to excellent discrimination (area
under the receiver operating characteristic (ROC) curve of
0.78 for the 30-day model and 0.79 for the one-year model).
In assessing the goodness-of-fit in both models, there was a
,1% difference between observed and expected mortality
within each quintile of likelihood, though the difference
between expected and observed mortality rates was signifi-
cant because of the large numbers. After adjustment,
thrombolytic therapy was no longer associated with a
significant 30-day survival benefit (odds ratio [OR] 1.01;
95% confidence interval [CI]: 0.94 to 1.09), but primary
angioplasty continued to be associated with lower mortality
(OR 0.79; 95% CI: 0.66 to 0.94). At one year, both
thrombolytic therapy (OR 0.84; 95% CI: 0.79 to 0.89) and
primary angioplasty (OR 0.71; 95% CI: 0.61 to 0.83) were
associated with lower mortality.
Subgroup analyses. In most of the stratified analyses,
mortality following thrombolytic therapy and primary an-
gioplasty was similar to the overall analysis. Patients treated
with thrombolytic therapy did not have a lower 30-day
mortality, adjusted for age, gender, electrocardiographic
criteria and availability of on-site angioplasty (Fig. 1). On
the other hand, younger patients, women, and patients with
.6 mm ST elevation had a statistically significantly lower
mortality with primary angioplasty. At one year, both
thrombolytic therapy and primary angioplasty were associ-
ated with a significantly lower mortality rate, independent of
age, gender, extent of ST elevation, and availability of
on-site angioplasty (Fig. 2). The benefit of primary angio-
plasty was greater than thrombolytic therapy at one year in
each stratum.
Patients with LBBB treated with reperfusion therapy had
an increased risk of 30-day and one-year mortality indepen-
dent of the reperfusion strategy. Because these patients were
so strikingly overrepresented in the group that underwent
no reperfusion (Table 2), we repeated the mortality outcome
comparison after omitting patients with LBBB from all
cohorts. Our results did not change appreciably.
The model developed to determine the likelihood of
receipt of thrombolytic therapy had an area under the ROC
curve of 0.77 and the goodness-of-fit statistic had a p-value
of 0.97, indicating an excellent fit. Using this model,
patients in the “highest-likelihood” quintile had a high
Table 1. Derivation of Primary Cohort and Ideal Subgroup
from CCP Population
Characteristic N
CCP population 234,769
Repeat admissions 23,773
Patients transferred into index hospital 42,177
Symptom onset to presentation .12 h 35,226
Symptom onset to presentation unknown 76,025
Absence of ST elevation or LBBB 152,477
Time of thrombolytic therapy or PTCA not documented 1,349
CCP qualifying patients 39,212
Active bleeding on arrival 799
History of bleeding disorder 236
Stroke within past year 90
Terminal illness 132
Primary cohort (patients without absolute
contraindications)
37,983
Symptom onset to presentation .6 h 4,793
Recent trauma 917
Recent surgery 913
Cardiopulmonary resuscitation 1,185
Prior stroke 4,610
BP .180/110 8,811
Use of warfarin with PT $16 or INR $2 1,167
Documentation of physician or patient refusal
of treatment
4,183
Cardiogenic shock on arrival 908
Cancer 794
Nursing home resident 1,371
Dementia 1,665
Do-not-resuscitate order 3,042
Ideal subgroup (patients without absolute or relative
contraindications)
16,305
Exclusion criteria from various cohorts are not mutually exclusive; patients may have
more than one exclusion criterion.
BP 5 blood pressure; CABG 5 coronary artery bypass surgery; CCP 5
Cooperative Cardiovascular Project; INR 5 International Normalized Ratio;
LBBB 5 left bundle branch block; PT 5 prothrombin time; PTCA 5 percutaneous
transluminal coronary angioplasty.
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probability of receiving thrombolysis, whereas those in the
lowest were unlikely to receive thrombolysis. After adjust-
ment for other factors, among patients in the “lowest-
likelihood” quintile to receive thrombolytic therapy, reper-
fusion therapy was associated with a nonsignificantly higher
30-day mortality and no significant benefit for one-year
mortality. Among patients in the “highest-likelihood” quin-
tile to receive thrombolytic therapy, reperfusion therapy was
associated with a nonsignificantly lower 30-day and one-
year mortality.
We repeated the logistic models for the 16,305 patients
considered the most ideal for reperfusion therapy (Table 4).
Table 2. Baseline Clinical and Hospital Characteristics of Patients Without Absolute
Contraindications to Thrombolytic Therapy
Characteristic
No
Reperfusion
Thrombolytic
Therapy p*
Primary
PTCA p†
N 22,043 (58.0%) 14,341 (37.8%) 1,599 (4.2%)
Demographics
Age (mean), years 77.7 6 7.4 73.4 6 6.1 0.001 73.7 6 6.1 0.001
Median age (25th, 75th) 78 (72, 83) 73 (69, 77) 73 (69, 78)
Female 50.4% 42.7% 0.001 43.0% 0.001
Caucasian 91.0% 92.7% 0.001 92.8% 0.02
Risk factors
Hypertension 63.2% 56.1% 0.001 57.4% 0.001
Diabetes 32.2% 22.6% 0.001 21.7% 0.001
Smoker 12.8% 20.8% 0.001 20.4% 0.001
Cardiac history
AMI 34.8% 20.6% 0.001 20.0% 0.001
Heart failure 26.9% 6.7% 0.001 6.3% 0.001
Bypass surgery 14.2% 7.2% 0.001 9.0% 0.001
Noncardiac history
Stroke 15.8% 6.7% 0.001 10.2% 0.001
COPD 20.1% 15.8% 0.001 16.3% 0.001
Dementia 6.2% 2.0% 0.001 1.4% 0.001
Limited mobility 19.3% 7.6% 0.001 8.0% 0.001
Urinary incontinence 6.9% 2.6% 0.001 3.8% 0.001
Cancer 2.6% 1.3% 0.001 2.6% 0.93
Nursing home resident 5.6% 0.9% 0.001 0.9% 0.001
DNR on arrival 11.2% 3.7% 0.001 2.4% 0.001
Clinical presentation
Symptom onset ,6 h 84.1% 92.3% 0.001 89.4% 0.001
Mean time after arrival (min) N/A 62 6 48 N/A 131 6 60 N/A
Early cardiac arrest 3.5% 2.5% 0.001 4.0% 0.27
Height (inches) 65.9 6 4.2 66.5 6 4.0 0.001 66.6 6 4.1 0.001
Weight (lbs) 159.0 6 35.8 167.7 6 34.2 0.001 167.3 6 33.2 0.001
Hypotension (SBP , 90) 1.5% 2.0% 0.001 2.8% 0.001
Bradycardia (HR , 60) 7.7% 17.9% 0.001 19.6% 0.001
Killip class
1 45.4% 63.4% 0.001 61.9% 0.001
2 12.6% 14.6% 0.001 13.1% 0.52
3 39.6% 20.1% 0.001 19.1% 0.001
4 2.4% 2.0% 0.03 5.9% 0.001
Electrocardiographic features
ST elevation $3 leads 73.2% 86.1% 0.001 86.1% 0.001
Sum ST elevation $6 mm 39.3% 55.9% 0.001 57.0% 0.001
Anterior location 48.7% 56.0% 0.001 56.9% 0.001
LBBB 23.4% 2.7% 0.001 3.9% 0.001
Serum creatinine (mg/dl) 1.4 6 0.9 1.2 6 0.5 0.001 1.2 6 0.8 0.001
Hospital characteristics
Annual AMI volume 201 6 174 186 6 155 0.001 316 6 205 0.001
PTCA available 42.2% 38.9% 0.001 100% 0.001
Attending physician is
cardiologist
25.0% 35.6% 0.001 59.1% 0.001
Admission therapies
Aspirin 78.3% 93.2% 0.001 93.8% 0.001
Beta blocker 43.7% 61.1% 0.001 53.5% 0.001
*Comparison of thrombolytic therapy to no reperfusion. †Comparison of primary coronary angioplasty to no reperfusion.
AMI 5 acute myocardial infarction; COPD 5 chronic obstructive pulmonary disease; DNR 5 do-not-resuscitate; HR 5
heart rate; LBBB 5 left bundle branch block; PTCA 5 percutaneous transluminal coronary angioplasty; SBP 5 systolic blood
pressure.
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In this subgroup, 8,487 (52.0%) of the patients received
thrombolytic therapy, 700 (4.3%) received primary angio-
plasty, and 7,118 (43.7%) did not undergo reperfusion
therapy. The 30-day and one-year mortality rates were
lowest for patients undergoing primary angioplasty; patients
receiving thrombolytic therapy had lower mortality than
those not receiving reperfusion therapy. After adjusting for
baseline characteristics, neither thrombolytic therapy nor
angioplasty was associated with a significant survival advan-
tage at 30 days. Both reperfusion strategies were associated
with a lower risk of one-year mortality.
We repeated the analyses after stratifying the thrombo-
lytic therapy group by door-to-therapy time and selection of
thrombolytic agent (Table 5). Administration of the throm-
bolytic agent within 30 min was associated with a trend
toward decreased 30-day mortality. The benefit of early
thrombolytic therapy was even more apparent at one year;
compared with patients in the no-reperfusion group, pa-
tients treated with streptokinase had a nonsignificant de-
crease in mortality, while those treated with tPA had a
significant reduction in mortality.
DISCUSSION
Previous studies. Our results provide new information
about the use and effectiveness of thrombolytic therapy in
Figure 1. Thirty-day mortality model for patients without absolute contraindications to thrombolytic therapy, stratified by clinical and hospital
characteristics. The odds ratio and 95% confidence intervals for thrombolysis (solid line) and primary angioplasty (dashed line) are compared with no
reperfusion strategy at 30 days. The results are stratified by clinical and hospital characteristics and also demonstrated for the combined study sample. Points
to the left of 1.00 indicate a benefit of the therapy whereas point estimates to the right of 1.00 indicate a detrimental effect.
Table 3. In-Hospital Events and Mortality Rates for Patients Without Absolute
Contraindications to Thrombolytic Therapy*
Characteristic No Reperfusion
Thrombolytic
Therapy p†
Primary
PTCA p‡
N 22,043 (58.0%) 14,341 (37.8%) 1,599 (4.2%)
Post-MI angina 31.5% 29.4% 0.001 23.6% 0.001
Heart failure 47.8% 29.4% 0.001 32.3% 0.001
Intracranial hemorrhage 0.1% 1.5% 0.001 0.1% 0.98
All strokes 2.7% 3.1% 0.07 2.1% 0.15
Hemorrhage 11.7% 22.5% 0.001 30.9% 0.001
Cardiac catheterization 23.3% 36.7% 0.001 100% 0.001
Coronary angioplasty 4.7% 10.0% 0.001 100% 0.001
Coronary artery bypass
surgery
4.3% 6.0% 0.001 10.1% 0.001
Mortality
30-day 20.6% 13.5% 0.001 13.0% 0.001
1-year 36.9% 19.5% 0.001 19.3% 0.001
*Reference group for statistical comparisons are patients not receiving reperfusion therapy. †Comparison of thrombolytic therapy
with no reperfusion. ‡Comparison of primary angioplasty with no reperfusion.
MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
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actual clinical practice among older patients hospitalized
with an AMI. Unlike the randomized controlled trials,
thrombolytic therapy in this community-based cohort was
not associated with significant or substantial benefit at 30
days when compared with no treatment. Our findings were
consistent across subgroups—including strata of age, gen-
der, electrocardiographic features and hospital on-site an-
gioplasty—and were evident among a restricted cohort of
patients considered “ideal” for therapy, a group that might
have been expected to be most similar to the cohort enrolled
in the trials.
Although the randomized clinical trials demonstrated a
benefit with thrombolytic therapy, the magnitude of the
benefit was smaller among older patients. In pooled analyses
there was a marked diminution of relative benefit associated
with thrombolytic therapy in the oldest age groups. Among
the 5,754 patients who were 75 years of age and older, the
relative reduction in mortality was roughly 4%, with an
absolute reduction of 1% (2). This mortality difference was
not statistically significant. The lack of benefit that we
observed in the patients who were 65 to 74 years of age does
contrast with the pooled result of a 16% relative reduction
and an absolute reduction of 2.6%. The difference in
outcomes between these randomized clinical trials and our
observational nationwide study likely reflects, in part, the
strict selection criteria of the clinical trials relative to clinical
practice. In addition to explicit study inclusion criteria
(clinical trials are, in general, designed to enroll patients
with the most favorable expected benefit-to-risk ratio),
there is clinical judgment applied in the decision to even
consider patients for enrollment in trials. This pre-
randomization patient selection is likely responsible for the
small numbers of elderly individuals enrolled in acute
reperfusion trials, and raises questions about how represen-
tative of their age cohort they are.
However, thrombolytic therapy was associated with an
improved long-term prognosis. The reason for a benefit of
thrombolytic therapy at one year that was not present at 30
days remains less clear. Prior studies demonstrate that the
significant short-term benefit of thrombolysis persists
Figure 2. One-year mortality model for patients without absolute contraindications to thrombolytic therapy, stratified by clinical and hospital
characteristics. The odds ratio and 95% confidence intervals for thrombolysis (solid line) and primary angioplasty (dashed line) are compared with no
reperfusion strategy at one year. The results are stratified by clinical and hospital characteristics and also demonstrated for the combined study sample. Points
to the left of 1.00 indicate a benefit of the therapy whereas point estimates to the right of 1.00 indicate a detrimental effect.
Table 4. Unadjusted and Adjusted Mortality Rates of Patients Ideal for Reperfusion Therapy*
Characteristic
No
Reperfusion
Thrombolytic
Therapy p† Primary PTCA p‡
N 7,118 (43.7%) 8,487 (52.0%) 700 (4.3%)
Unadjusted mortality rates
30-day 14.8% 10.6% 0.001 8.9% 0.001
1-year 29.4% 15.8% 0.001 13.1% 0.001
Adjusted mortality rates
30-day 1.00 1.05 (0.93, 1.19)‡ 0.78 (0.58, 1.05)
1-year 1.00 0.85 (0.77, 0.94) 0.63 (0.49, 0.81)
*Reference group for odds ratios are patients who did not receive early reperfusion therapy. †Comparison of thrombolytic therapy
to no reperfusion. ‡Comparison of primary coronary angioplasty to no reperfusion.
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through one year and may even be present as far as 10 years
after the AMI (17–19), but that the benefit does not
increase over time. Our results may reflect an early hazard of
thrombolysis, an attenuated early benefit of thrombolysis
among older patients or a selection effect for which we were
unable to adjust. The early hazard of thrombolytic therapy,
particularly stroke and hemorrhage, is higher among older
patients, thereby reducing the potential 30-day benefit.
Alternatively, the benefit of an “open artery” resulting from
thrombolysis may not be limited to myocardial salvage and
may occur later as a result of improved left ventricular model-
ing. More likely, the results reflect the absence of a true benefit
of thrombolytic therapy in older patients and a tendency to
administer thrombolytic agents to healthier patients. Although
we adjusted for many prognostic factors and comorbid condi-
tions, there may have been residual confounders.
In contrast, primary angioplasty was associated with an
improved survival at both 30 days and one year. In a recent
investigation using the same database, we found that pa-
tients treated with primary angioplasty had a moderate
improvement in survival compared with patients treated
with thrombolytic therapy (5). In an ideal restricted cohort,
the magnitude of benefit was small and not statistically
significant. In that investigation we did not include an
assessment of the “no-treatment” strategy. The current
study suggests that primary angioplasty, in contrast to
thrombolytic therapy, may be associated with an early
survival benefit. Although both reperfusion strategies were
associated with improved one-year survival, the benefit of
primary angioplasty was greater than that of thrombolytic
therapy, particularly in patients over age 85. Our results are
consistent with a recent meta-analysis of randomized trials
of angioplasty versus thrombolysis showing a modest benefit
of primary angioplasty over thrombolytic therapy in the
management of AMI (3). It is interesting that analyses of
other observational databases that examined younger co-
horts (median age 60 years) suggest that the outcomes of
both strategies may be similar (20,21). The improved
survival associated with primary angioplasty in the CCP
cohort (median age 75 years) may reflect a greater benefit of
this reperfusion strategy among older patients.
Another important finding in this study is the low
utilization of reperfusion therapy in older Americans.
Among patients without absolute contraindications to
thrombolytic therapy, only 42% received either thrombolytic
therapy or primary angioplasty. Even after restricting the
cohort to a subgroup of patients considered ideal for
thrombolytic therapy, the proportion of patients receiving
reperfusion therapy remained low (56.3%). Although there
may have been factors for which we could not account, it is
unclear why so many otherwise eligible and appropriate
patients did not receive reperfusion therapy.
Study limitations. The most important limitation of this
study is the nonrandom assignment of treatment strategy.
Consequently, we cannot exclude the possibility that un-
measured selection factors influenced our results. To address
this issue, we used methods that minimize the problems
inherent to drawing inferences from observational data (22).
For other studies in which we applied this methodology,
aspirin and beta-blockers were found to be associated with
a similar relative risk reduction in a population-based
sample of older patients as in the randomized trials (23,24).
Conclusions. We found evidence supporting the one-year,
but not 30-day, benefit of thrombolytic therapy for patients
65 years of age and older. These findings are surprising and
not entirely consistent with the randomized trials. In con-
trast, the results with primary angioplasty are consistent
with previous findings. The results can be interpreted as
indicating that older patients benefit from thrombolytic
therapy in the long run. On the other hand, it may be that
the intervention is not as effective, on average, in the older
population as it is in younger patients, and that the
long-term benefit is the result of residual confounding
associated with treating patients who have less comorbidity
and better long-term prognosis. Thus, the effectiveness of
thrombolytic therapy and the role of primary angioplasty in
the very elderly remain somewhat uncertain. Overall, our
findings generally support the current ACC/AHA guide-
lines that reflect the absence of a consensus opinion in
administering thrombolytic therapy to older patients. Our
findings also indicate a need for further investigation to
determine the best approach to the treatment of older
patients with suspected AMI and ST-segment elevation or
LBBB.
Reprint requests and correspondence: Dr. Harlan M. Krum-
holz, Yale University School of Medicine, 333 Cedar St., P.O. Box
208025, New Haven, Connecticut 06520-8025. E-mail:
harlan.krumholz@yale.edu.
Table 5. Thirty-Day and One-Year Mortality Models Stratified by Thrombolytic Therapy Characteristics
Logistic Model Features Neither
30-Day Mortality 1-Year Mortality
Thrombolytic
Therapy PTCA
Thrombolytic
Therapy PTCA
Early thrombolytic therapy (#30 min) 1.00 0.93 (0.85, 1.01) 0.79 (0.67, 0.94) 0.77 (0.71, 0.83) 0.71 (0.62, 0.83)
Later thrombolytic therapy 1.27 (1.16, 1.39) 1.01 (0.93, 1.09)
Streptokinase 1.00 1.20 (1.07, 1.34) 0.80 (0.68, 0.96) 0.99 (0.90, 1.09) 0.72 (0.62, 0.83)
tPA 1.03 (0.95, 1.12) 0.83 (0.77, 0.89)
PTCA 5 percutaneous transluminal coronary angioplasty; tPA 5 tissue plasminogen activator.
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